Advances in genetic screening technologies have considerably accelerated the discovery of rare alpha-1-antitrypsin (AAT) variants. Expression in cellular models is an effective approach to evaluate the pathogenic potential of these new AAT variants, whose clinical significance would otherwise remain uncertain. Here we provide a detailed description of established methods for in vitro characterization of AAT coding variants expressed in HEK293T/17 cells. The protocols include determination of secretion efficiency, the tendency to form polymeric chains and the anti-elastase inhibitory activity.
Keywords: Alpha-1-antitrypsin polymers; Alpha-1-antitrypsin rare variants; Anti-elastase inhibitory activity; Pathogenicity prediction; SERPINA1.
© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.